Skip to main content

Table 2 Serum biomarkers

From: Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis

 

Healthy subjects

Untreated IPF

Treated IPF

IGF-1 (ng/ml)

31 (7–67)

20 (9–102)*

25 (11–57)

IGF-2 (ng/ml)

710 (401–2232)

590 (210–1027)*

586 (282–920)**

IGFBP-1 (ng/ml)

11 (0–180)

22 (4–110)*

9 (1–107)

IGFBP-2 (ng/ml)

94 (34–211)

206 (113–317)***

153 (32–291)** °

IGFBP-3 (ng/ml)

2132 (1207–4059)

1536 (534–2556)*

2032 (893–3505)

Molar ratio IGF-1 : IGFBP-1

12 (1–314)

3,5 (0,3–36,3)*

9 (1–152)

Molar ratio IGF-1 : IGFBP-2

1,8 (0,2–6,2)

0,4 (0–4,3)***

0,7 (0,3–5,2)*

Molar ratio IGF-1 : IGFBP-3

0,06 (0,02–0,12)

0,05 (0,03–0,25)

0,05 (0,03–0,1)

Molar ratio IGF-2 : IGFBP-1

247 (20–6735)

110 (11–769)*

259 (20–2429)

Molar ratio IGF-2 : IGFBP-2

40 (10–202)

14 (5–28)***

19 (7–89)**

Molar ratio IGF-2 : IGFBP-3

1,4 (0,8-5,1)

1,6 (0,6-2,2)

1,2 (0,9-1,8)

TGF-β (ng/ml)

11 (3–21)

11 (5–22)

9 (4–17)

KL-6 (ng/ml)

262 (83–596)

1050 (314–4951)***

889 (359–6168)***

  1. Data are expressed as median (min-max)
  2. *p < 0.05 **p < 0.001 ***p < 0.0001 compared to healthy subjects
  3. °p < 0.05 °°p < 0.001 °°°p < 0.0001 compared to untreated IPF